# Paclitaxel and Carboplatin Combination as 1st Line Treatment in Ovarian Carcinomas

> **NCT00750386** · PHASE1,PHASE2 · COMPLETED · sponsor: **Hellenic Oncology Research Group** · enrollment: 50 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT00750386
- **Lead sponsor:** Hellenic Oncology Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2011-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00750386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00750386, "Paclitaxel and Carboplatin Combination as 1st Line Treatment in Ovarian Carcinomas". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00750386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*